EXHIBIT 10.9

                                AMENDMENT TEN TO
                              DEVELOPMENT AGREEMENT

         This Amendment TEN, made as of April 16, 2002 ("Effective Date")
between SRI International, a California, non-profit and public benefit
corporation, having a place of business located at 333 Ravenswood Avenue, Menlo
Park, CA 94025 (hereinafter "SRI") and Lipid Sciences Incorporated, an Arizona
corporation, having a place of business located at 7068 Koll Center Parkway,
Suite 401, Pleasanton, CA 94566 (hereinafter "LSI").

         WHEREAS, SRI and LSI have entered into a development agreement having
an effective date of October 6, 2000, and which includes the following
Amendments: Amendment One dated March 8, 2001, Amendment Two dated March 28,
2001; Amendment Three dated May 12, 2001; Amendment Four dated May 13, 2001,
Amendment Five dated May 13, 2001, Amendment Six dated December 5, 2001,
Amendment Seven dated October 6, 2000, Amendment Eight dated February 13, 2002,
and Amendment Nine dated April 15, 2002 (hereinafter individually and
collectively "Development Agreement") and which the parties hereby amend; and

         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, SRI and LSI agree as follows:

1.       For consistency and unless otherwise defined herein all initially
         capitalized terms shall have the meaning set forth in the Development
         Agreement.

2.       The scope of work and project cost of $29,800 (excluding travel and all
         non-labor expenses), are attached hereto as Exhibit A (SRI Proposal BDC
         02-079). The parties agree that this effort is outside of the scope of
         the Phase II Development Plan of the Development Agreement

3.       Unless expressly amended by this Amendment Ten, all other terms and
         conditions of the Development Agreement shall remain in full force and
         effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date last subscribed below.


SRI International                    Lipid Sciences, Incorporated


By: /s/ V. Rene Harmount             By: /s/ Barry D. Michaels
    --------------------                 ---------------------
    V. Rene Harmount                     Barry D. Michaels
    Group Manager, Contracts             Chief Financial Officer




                                   EXHIBIT A

                     SRI INTERNATIONAL PROPOSAL #BDC 02-079

                               STATEMENT OF WORK


         SRI shall provide assistance to LSI with the transfer and validation of
the GC method to determine the residual solvents in delipidated plasma from SRI
to the Progen Industries Limited lab in Brisbane, Australia for an estimated 170
labor hours (including travel time) at a price of $29,800. This price does not
include non-labor expenses such as air fare, per diem or other non-labor
expenses. LSI shall arrange for the payment of such expenses separately. The
assistance includes conference calls and e-mail consultations, documents review,
help with cGMP laboratory set up, Agilent Chemstation and GC operation training,
data analysis training and template set up, as well as ten days of on site
assistance with validation protocol execution by SRI personnel (one person) from
April 22 to May 1.